CSL : Results Presentation

For immediate release

18 August 2021

RESULTS PRESENTATION

FOR THE FULL YEAR ENDED 30 JUNE 2021

Melbourne, Australia - CSL (ASX:CSL; USOTC:CSLLY)

Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly.

The live briefing will be webcast and can be viewed at https://csl.webcastcloud.com/event?eventid=cc1ba0b2-0ddc-4c36-a8bc-da89aec8c6d8.Please note that this link will expire after the webcast concludes.

A recording of the webcast will be made available later in the day at: https://investors.csl.com/site/investors/financial-results-and-information

Authorised for lodgment by:

Fiona Mead

Company Secretary

For further information, please contact:

Investors:	Media:
Mark Dehring	Jimmy Baker
VP Investor Relations	Communications, Asia Pacific
P: [phone]	P: [phone]
E: [e-mail]	E: [e-mail]

CSL Limited

2021 Full Year

Results

18 August, 2021

Paul Perreault	Joy Linton
CEO and Managing Director	CFO

Legal

Notice

2

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.auThis presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research and risk management practices. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project," "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements. . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL's ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

CEO Overview

Paul Perreault

CEO & Managing Director

Highlights1

Revenue up 10% with net profit after tax up 10%

CSL Behring

• HIZENTRA® +15%
• HAEGARDA® +14%
• KCENTRA® +7%
• ALBUMIN +61%
• Digital transformation initiatives

Seqirus

• Seasonal influenza vaccines +41%
• Record volume ~130 million doses distributed globally
• Next generation influenza vaccine manufacturing facility to be constructed

• COVID-19 has produced a
	headwind for Behring and a
	tailwind for Seqirus
•	Plasma collections have
	been challenging however
	multiple initiatives are
	driving solid growth
•	Continued capital
	expenditure and R&D

Critical operations maintained during COVID-19

pandemic demonstrating CSL's resilience and agility

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

4

investment places CSL in a

position to emerge strongly

post COVID-19